Kolexia
Eymard Jean-Christophe Oncologie médicale
Eymard Jean-Christophe
Oncologie médicale
Institut Godinot
Reims, France
192 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de la prostate Métastase tumorale Tumeurs prostatiques résistantes à la castration Carcinomes Néphrocarcinome Récidive tumorale locale Adénocarcinome Tumeurs embryonnaires et germinales

Collaborateurs

Voir plus
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Petit Thierry
Petit Thierry
Centre Paul Strauss, Strasbourg, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
A+A
26 collaboration(s)
Dernière en 2023
IQVIA
20 collaboration(s)
Dernière en 2023
Janssen
17 collaboration(s)
Dernière en 2023
Pfizer
15 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors: A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Essai Clinique (Unicancer)   01 février 2024
2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer: Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Essai Clinique (Novartis)   05 septembre 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
European urology   02 juin 2023
P010 - E-Monitoring de la qualité de vie des patients atteints d'un adénocarcinome du rein localement avancé ou métastatique et traités par inhibiteurs de la tyrosine kinase : résultats de l’étude de faisabilité QUANARIE
EPICLIN 202317e Conférence francophone d’Épidémiologie Clinique30e Journées des statisticiens des Centres de Lutte contre le Cancer   01 mai 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
British journal of cancer   03 avril 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast cancer research and treatment   29 mars 2023
ESME-MBC: Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
Essai Clinique (Seagen)   16 mars 2023
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
Cancers   13 février 2023